AI-guided lipid nanoparticle design makes RNA vaccines more heat-tolerant
MIT researchers used an AI algorithm to optimize lipid nanoparticles that carry mRNA, improving the vaccines' resistance to heat. Their formulations remained stable for up to a year at room temperature and for two months at roughly 38°C. In mice, a COVID-19 vaccine using these particles produced an immune response comparable to that of a Moderna-like RNA vaccine.
MIT scientists turned to machine learning to refine lipid nanoparticles for mRNA delivery. The method predicted useful formulations from limited experimental data, cutting trial numbers. In tests, the vaccines stayed usable for a year at room temperature or two months near 38°C. In mice, a COVID-19 formulation triggered immunity comparable to a Moderna-like RNA vaccine.
RNA degrades easily, so lipid nanoparticles shield it and aid cell entry. Conventional RNA-LNP vaccines often need -20 to -80°C storage, complicating transport to places lacking cold chains. The work, published in Nature Biotechnology, also points toward microneedle patches. Excipients such as sugars, salts, or polymers had been tried previously.
If heat-stable RNA vaccines hold up in humans, they could simplify distribution in warm or remote regions with limited cold-chain infrastructure. Clinics, pharmacies, and vaccination campaigns may face fewer storage barriers, potentially expanding access. Manufacturers might also explore microneedle patches, which could make administration easier. However, mouse results and formulation stability do not guarantee clinical success; regulatory and manufacturing validation would still be needed.